Frequently Asked Questions
The market is segmented based on U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs (Prolastin, Zemaira/Respreeza, Glassia, Aralast NP, Others), Gene Type (Type Pizz, Type Pims, Type Pimz, Others), Application (Lung Disease, Liver Disease), Population Type (Adults, Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Us Alpha 1 Antitrypsin Deficiency Aatd Augmentation Therapy Market size was valued at USD 613.93 USD Million in 2022.
The Us Alpha 1 Antitrypsin Deficiency Aatd Augmentation Therapy Market is projected to grow at a CAGR of 9% during the forecast period of 2023 to 2030.
